Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322014743> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2322014743 endingPage "23" @default.
- W2322014743 startingPage "23.2" @default.
- W2322014743 abstract "The licensing of belimumab for use in active systemic lupus erythematosus (SLE) has ushered in a new era for the connective tissue diseases (CTDs) based on a better understanding of disease pathogenesis. Genome-wide association studies have been used to identify a number of new therapeutic pathways. Anti-B-cell therapy is proposed for other CTDs such as primary Sjogren’s syndrome (PSS) and inflammatory myositis. Other biological therapies – for example targeted at interferons and the innate immune system may also be on the horizon for several of these conditions. Eculizumab, a complement inhibitor has been used successfully in cases of catastrophic anti-phospholipid syndrome. One theme across the connective tissue diseases is to optimize existing therapies and reduce corticosteroid and cyclophosphamide usage. In SLE for example, the use of mycophenolate mofetil to replace cyclophosphamide in many cases of lupus nephritis and steroid-free regimes are also being evaluated. IVIG may also have a role in reducing steroid usage e.g. in myositis flare. In scleroderma, regular screening has improved survival, particularly with regard to earlier intervention for lung fibrosis and pulmonary hypertension. Interstitial lung disease is also common in myositis. Careful attention to nutrition and other gastrointestinal complications have improved patients’ general health. Another theme is improved classification of patients into more specific subgroups for targeted management. New antibodies with clinical relevance continue to be discovered: For example - in myositis anti-TIFF antibodies are associated with cancer associated dermatomyositis and anti-MDA5 antibodies with interstitial lung disease. In scleroderma anti-U11/U12 RNP antibodies identify patients with lung fibrosis. International collaborations have been an important driver of new approaches to assessment and therapies. In SLE the SLICC and BILAG groups have been long-established. EUSTAR in scleroderma, EUMYONET in myositis and the UKPSSR and EULAR working group in Sjogren’s are all examples of this trend. <h3>Acknowledgements</h3> With thanks to: Dr David D’Cruz, Prof Chris Denton, Prof Caroline Gordon, Dr Patrick Gordon and Dr Voon Ong. <h3>Disclosure of Interest</h3> S. Bowman Consultant for: Merck-Serono" @default.
- W2322014743 created "2016-06-24" @default.
- W2322014743 creator A5044642567 @default.
- W2322014743 date "2013-06-01" @default.
- W2322014743 modified "2023-09-26" @default.
- W2322014743 title "SP0092 Latest advances in connective tissue disorders" @default.
- W2322014743 doi "https://doi.org/10.1136/annrheumdis-2012-eular.1567" @default.
- W2322014743 hasPublicationYear "2013" @default.
- W2322014743 type Work @default.
- W2322014743 sameAs 2322014743 @default.
- W2322014743 citedByCount "0" @default.
- W2322014743 crossrefType "journal-article" @default.
- W2322014743 hasAuthorship W2322014743A5044642567 @default.
- W2322014743 hasConcept C111684460 @default.
- W2322014743 hasConcept C126322002 @default.
- W2322014743 hasConcept C142724271 @default.
- W2322014743 hasConcept C159654299 @default.
- W2322014743 hasConcept C16005928 @default.
- W2322014743 hasConcept C180032290 @default.
- W2322014743 hasConcept C203014093 @default.
- W2322014743 hasConcept C2776153627 @default.
- W2322014743 hasConcept C2776670291 @default.
- W2322014743 hasConcept C2776912625 @default.
- W2322014743 hasConcept C2777543607 @default.
- W2322014743 hasConcept C2777714996 @default.
- W2322014743 hasConcept C2777991916 @default.
- W2322014743 hasConcept C2778751314 @default.
- W2322014743 hasConcept C2779075594 @default.
- W2322014743 hasConcept C2779123688 @default.
- W2322014743 hasConcept C2779134260 @default.
- W2322014743 hasConcept C2779387793 @default.
- W2322014743 hasConcept C2779912601 @default.
- W2322014743 hasConcept C2779967694 @default.
- W2322014743 hasConcept C2781232998 @default.
- W2322014743 hasConcept C3008058167 @default.
- W2322014743 hasConcept C524204448 @default.
- W2322014743 hasConcept C71924100 @default.
- W2322014743 hasConceptScore W2322014743C111684460 @default.
- W2322014743 hasConceptScore W2322014743C126322002 @default.
- W2322014743 hasConceptScore W2322014743C142724271 @default.
- W2322014743 hasConceptScore W2322014743C159654299 @default.
- W2322014743 hasConceptScore W2322014743C16005928 @default.
- W2322014743 hasConceptScore W2322014743C180032290 @default.
- W2322014743 hasConceptScore W2322014743C203014093 @default.
- W2322014743 hasConceptScore W2322014743C2776153627 @default.
- W2322014743 hasConceptScore W2322014743C2776670291 @default.
- W2322014743 hasConceptScore W2322014743C2776912625 @default.
- W2322014743 hasConceptScore W2322014743C2777543607 @default.
- W2322014743 hasConceptScore W2322014743C2777714996 @default.
- W2322014743 hasConceptScore W2322014743C2777991916 @default.
- W2322014743 hasConceptScore W2322014743C2778751314 @default.
- W2322014743 hasConceptScore W2322014743C2779075594 @default.
- W2322014743 hasConceptScore W2322014743C2779123688 @default.
- W2322014743 hasConceptScore W2322014743C2779134260 @default.
- W2322014743 hasConceptScore W2322014743C2779387793 @default.
- W2322014743 hasConceptScore W2322014743C2779912601 @default.
- W2322014743 hasConceptScore W2322014743C2779967694 @default.
- W2322014743 hasConceptScore W2322014743C2781232998 @default.
- W2322014743 hasConceptScore W2322014743C3008058167 @default.
- W2322014743 hasConceptScore W2322014743C524204448 @default.
- W2322014743 hasConceptScore W2322014743C71924100 @default.
- W2322014743 hasIssue "Suppl 3" @default.
- W2322014743 hasLocation W23220147431 @default.
- W2322014743 hasOpenAccess W2322014743 @default.
- W2322014743 hasPrimaryLocation W23220147431 @default.
- W2322014743 hasRelatedWork W2140630139 @default.
- W2322014743 hasRelatedWork W2322014743 @default.
- W2322014743 hasRelatedWork W2405735728 @default.
- W2322014743 hasRelatedWork W2412495128 @default.
- W2322014743 hasRelatedWork W2514007641 @default.
- W2322014743 hasRelatedWork W2755026448 @default.
- W2322014743 hasRelatedWork W3014585118 @default.
- W2322014743 hasRelatedWork W3164968587 @default.
- W2322014743 hasRelatedWork W4283689755 @default.
- W2322014743 hasRelatedWork W4283710623 @default.
- W2322014743 hasVolume "71" @default.
- W2322014743 isParatext "false" @default.
- W2322014743 isRetracted "false" @default.
- W2322014743 magId "2322014743" @default.
- W2322014743 workType "article" @default.